Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lin Shen

Showing results (1491-1500 of 1,553) with videos related to

Pageof 156
Sort By:
Translational Psychiatry|July 15, 2020
Capsaicin consumption reduces brain amyloid-beta generation and attenuates Alzheimer's disease-type pathology and cognitive deficits in APP/PS1 miceJun Wang, Bin-Lu Sun, Yang Xiang, et al.
Chinese Journal of Cancer|December 24, 2016
Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumabMasahito Kotaka, Ruihua Xu, Kei Muro, et al.
Cancer Communications (London, England)|March 20, 2019
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancerFeng-Hua Wang, Lin Shen, Jin Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2026
Allogeneic B7-H3-targeted CAR-Vδ1T cell therapy in advanced solid tumors: A phase I studyChang Liu, Jiarui Li, Dan Liu, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 16, 2023
Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinibJianwei Zhang, Haibin Zhu, Lin Shen, et al.
Acta Neuropathologica|August 4, 2018
Physiological clearance of tau in the periphery and its therapeutic potential for tauopathiesJun Wang, Wang-Sheng Jin, Xian-Le Bu, et al.
Lancet (London, England)|August 29, 2021
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 studyJong-Mu Sun, Lin Shen, Manish A Shah, et al.
The Lancet. Oncology|May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 studyJing Huang, Jianming Xu, Yun Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 TrialYelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.
BMJ (Clinical Research Ed.)|April 20, 2022
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trialZhihao Lu, Junye Wang, Yongqian Shu, et al.
Pageof 156

Showing results (1491-1500 of 1,553) with videos related to

Sort By:
Pageof 156
Translational Psychiatry|July 15, 2020
Capsaicin consumption reduces brain amyloid-beta generation and attenuates Alzheimer's disease-type pathology and cognitive deficits in APP/PS1 miceJun Wang, Bin-Lu Sun, Yang Xiang, et al.
Chinese Journal of Cancer|December 24, 2016
Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumabMasahito Kotaka, Ruihua Xu, Kei Muro, et al.
Cancer Communications (London, England)|March 20, 2019
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancerFeng-Hua Wang, Lin Shen, Jin Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2026
Allogeneic B7-H3-targeted CAR-Vδ1T cell therapy in advanced solid tumors: A phase I studyChang Liu, Jiarui Li, Dan Liu, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 16, 2023
Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinibJianwei Zhang, Haibin Zhu, Lin Shen, et al.
Acta Neuropathologica|August 4, 2018
Physiological clearance of tau in the periphery and its therapeutic potential for tauopathiesJun Wang, Wang-Sheng Jin, Xian-Le Bu, et al.
Lancet (London, England)|August 29, 2021
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 studyJong-Mu Sun, Lin Shen, Manish A Shah, et al.
The Lancet. Oncology|May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 studyJing Huang, Jianming Xu, Yun Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 TrialYelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.
BMJ (Clinical Research Ed.)|April 20, 2022
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trialZhihao Lu, Junye Wang, Yongqian Shu, et al.
Pageof 156